Literature DB >> 30461263

Previously Uncharacterized Vacuolar-type ATPase Binding Site Discovered from Structurally Similar Compounds with Distinct Mechanisms of Action.

Andrew C Wang1, Helen T Pham1, Jennifer M Lipps1, Scott M Brittain1, Edmund Harrington1, Yuan Wang1, Fred J King2, Carsten Russ1, Xuewen Pan1, Dominic Hoepfner3, John Tallarico1, Yan Feng1, Rishi K Jain1, Markus Schirle1, Jason R Thomas1.   

Abstract

Using a comprehensive chemical genetics approach, we identified a member of the lignan natural product family, HTP-013, which exhibited significant cytotoxicity across various cancer cell lines. Correlation of compound activity across a panel of reporter gene assays suggested the vacuolar-type ATPase (v-ATPase) as a potential target for this compound. Additional cellular studies and a yeast haploinsufficiency screen strongly supported this finding. Competitive photoaffinity labeling experiments demonstrated that the ATP6V0A2 subunit of the v-ATPase complex binds directly to HTP-013, and further mutagenesis library screening identified resistance-conferring mutations in ATP6V0A2. The positions of these mutations suggest the molecule binds a novel pocket within the domain of the v-ATPase complex responsible for proton translocation. While other mechanisms of v-ATPase regulation have been described, such as dissociation of the complex or inhibition by natural products including bafilomycin A1 and concanamycin, this work provides detailed insight into a distinct binding pocket within the v-ATPase complex.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30461263     DOI: 10.1021/acschembio.8b00656

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  3 in total

1.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  Leslie N Aldrich; Joanna E Burdette; Esperanza Carcache de Blanco; Christopher C Coss; Alessandra S Eustaquio; James R Fuchs; A Douglas Kinghorn; Amanda MacFarlane; Brittney K Mize; Nicholas H Oberlies; Jimmy Orjala; Cedric J Pearce; Mitch A Phelps; Liva Harinantenaina Rakotondraibe; Yulin Ren; Djaja Doel Soejarto; Brent R Stockwell; Jack C Yalowich; Xiaoli Zhang
Journal:  J Nat Prod       Date:  2022-02-25       Impact factor: 4.803

2.  PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer.

Authors:  Amrita Salvi; Alexandria N Young; Andrew C Huntsman; Melissa R Pergande; Melissa A Korkmaz; Rathnayake A Rathnayake; Brittney K Mize; A Douglas Kinghorn; Xiaoli Zhang; Kiira Ratia; Markus Schirle; Jason R Thomas; Scott M Brittain; Claude Shelton; Leslie N Aldrich; Stephanie M Cologna; James R Fuchs; Joanna E Burdette
Journal:  Cell Death Dis       Date:  2022-01-10       Impact factor: 8.469

3.  Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry.

Authors:  Caroline B Plescia; Aaron R Lindstrom; Maritza V Quintero; Patrick Keiser; Manu Anantpadma; Robert Davey; Robert V Stahelin; V Jo Davisson
Journal:  ACS Infect Dis       Date:  2022-03-31       Impact factor: 5.578

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.